Avery Therapeutics, Inc. — SEC Form D Filing
Avery Therapeutics, Inc. filed an SEC Form D on September 21, 2026, reporting $8.47M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 21, 2026
- Amount reported
- $8.47M
- Round stage
- Pre-Seed
- Industry
- Biotechnology
- Website
- https://averythera.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffering from conditions requiring immunomodulatory biologic therapeutics lack novel treatment options.
Solution
Avery Therapeutics is developing novel immunomodulatory biologic therapeutics.
Verdict
Investors backed Avery Therapeutics at the pre-seed stage because the inherent market size and impact potential of a novel biologic for immunomodulation was understood, not because of a de-risked product path or detailed commercial strategy. This cleared because investors bought into the *idea* of a new therapeutic paradigm with the belief that preclinical promise could translate, implicitly betting on the team's scientific acumen to navigate early development. The upside was inherently capped by the long, capital-intensive regulatory hurdles and competitive landscape typical for biologic drug development.
Source: SEC EDGAR Form D filing